banner

The official advocacy organization for pharmacist women in the United States

Advertisement

Pharmacist Moms Group

45,000+ Members

45,000+ Members

Over 6 Million posts, comments and reactions in 2020

Over 6 Million posts, comments and reactions in 2020

60,000+ Followers on social media platforms

60,000+ Followers on social media platforms

The Largest Community of Women Pharmacists in the US

pharmacist moms

Founded in 2017, Pharmacists Moms Group was created to provide women pharmacists the opportunity to network, collaborate and offer genuine feedback in a closed-door, trusted setting. The organization has quickly grown to over 45,000 members and 60,000 followers on our social media platforms.

Pharmacy News
View More
Diabetes Cohort Study Reveals Prolonged Delays in Pneumococcal Vaccination

Time-to-vaccination data from a large diabetes cohort reveal delayed, incomplete uptake of pneumococcal vaccination, with age and citizenship emerging as the strongest predictors.

Fast-Acting Meloxicam Demonstrates Postoperative Pain Relief and Opioid-Sparing Potential

The phase 3 findings support MR-107A-02's potential as a nonopioid option for certain patients with moderate to severe acute pain.

Consensus Study Sets Standard Outcomes for CKD Pharmacist Trials

Five "essential" outcomes, including medication error and adherence, should anchor every pharmacist intervention study in chronic kidney disease.

Formulary, Adherence, and Whole-Person Support in Multiple Sclerosis Care

Melissa Seifert, PharmD of UPMC Health Plan explains how managed care pharmacists guide DMT selection and address adherence barriers in patients with MS.

How UPMC's Integrated Model Supports Members With Multiple Sclerosis

A clinical pharmacy specialist at UPMC Health Plan discusses how pharmacists help select disease-modifying therapies, address adherence barriers, and coordinate whole-person care for those with MS.

Why Didn’t IV Arginine Improve Acute Sickle Cell Pain? STArT Trial Investigator Explains

In an interview with Pharmacy Times, Claudia R. Morris, MD, lead investigator and author of the phase 3 STArT trial, discusses why intravenous arginine did not shorten time to crisis resolution and how institutional variation, pain heterogeneity, shorter hospital stays, and treatment timing may have influenced the findings.

Advertisement
Advertisement

Official Media Partner

Official Media Partner

Official CE Partner

Official CE Partner

Founder of Women Pharmacist Day

Founder of Women Pharmacist Day
pharmacist moms group logo
Stay In Touch
an mjh life sciences brand

© 2021 MJH Life Sciences and Pharmacy Times®. All rights reserved.

Privacy Policy